Intensive reduction of high normal blood pressures: PRINT-TAHA9 randomized clinical trial

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Associate Professor Armin Attar

Shiraz University of Medical Sciences, Shiraz (Iran (Islamic Republic of))

7 More presentations in this session

Presentation thumbnail

Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107

Doctor M. Freeman (Boston, US)

Abstract Slides

Presentation thumbnail

Differentiated approach to the treatment of uncomplicated hypertensive crisis

Doctor M. Sadulloeva (Tashkent, UZ)

Abstract Slides

Presentation thumbnail

Blockade of the renin-angiotensin system as a therapeutic target of NAFLD: results of an experimental model of hypercholesterolemia

Professor D. Bertolim Precoma (Campina Grande do Sul, BR)

Abstract Slides

Presentation thumbnail

Hydrochlorothiazide does not lead to phototoxic reactions and DNA damage in healthy volunteers the HCTox study

Doctor F. Goetzinger (Basel, CH)

Abstract Slides

Presentation thumbnail

Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients

Doctor A. Liontos (Ioannina, GR)

Abstract Slides

Access the full session

Session thumbnail

Hypertension - Pharmacotherapy

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

The floor is yours: bring your questions about optimal blood pressure control for organ protection - expert panel

Congress Presentation

Hypertension, diabetes, and the kidney: a triple threat for adverse cardiovascular events?

Congress Presentation

Hypertension and glucose

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources